$22.93
0.00%
Nasdaq, Fri, Nov 15 2024
ISIN
US5150691021
Symbol
LABP
Sector
Industry

Landos Biopharma Inc Stock price

$22.93
+0.00 0.00% 1M
+0.63 2.83% 6M
+19.27 526.50% YTD
+18.94 474.69% 1Y
-117.17 83.63% 3Y
-137.07 85.67% 5Y
-137.07 85.67% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.00%
ISIN
US5150691021
Symbol
LABP
Sector
Industry

Key metrics

Market capitalization $71.68m
Enterprise Value $42.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-25.24m
Free Cash Flow (TTM) Free Cash Flow $-20.81m
Cash position $29.05m
EPS (TTM) EPS $-3.99
P/E forward negative
Short interest 0.09%
Show more

Is Landos Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Landos Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Landos Biopharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Landos Biopharma Inc:

Buy
100%

Financial data from Landos Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
0% 0%
-
- Research and Development Expense 12 12
35% 35%
-
-25 -25
21% 21%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
21% 21%
-
Net Profit -25 -25
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Landos Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Landos Biopharma Inc Stock News

Neutral
PRNewsWire
6 months ago
-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).
Neutral
Business Wire
6 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (w...

Company Profile

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Head office United States
CEO Gregory Oakes
Employees 19
Founded 2017
Website www.landosbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today